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Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a cephalosporin
with  in vitro bactericidal activity against Gram-positive organisms, including methicillin-
susceptible  and -resistant Staphylococcus aureus, -haemolytic and viridans group
streptococci,  and Streptococcus pneumoniae, as well as common Gram-negative organisms.
In  this study a total of 986 isolates collected in 2010 from patients in 15 medical centers in
ﬁve  Latin American countries from the Assessing Worldwide Antimicrobial Resistance Eval-
uation Program were identiﬁed as community-acquired respiratory tract or skin and soft
tissue  infection pathogens. Ceftaroline was the most potent agent tested against S. pneumo-
niae  with a MIC90 value (0.12 g/mL) that was eight-fold lower than ceftriaxone, levoﬂoxacin,
and  linezolid. Its spectrum of coverage (100.0% susceptible) was similar to tigecycline, line-
zolid,  levoﬂoxacin and vancomycin. Against Haemophilus inﬂuenzae and Moraxella catarrhalis,
ceftaroline  was the most active agent tested. The activity of ceftaroline against S. aureus
(including  MRSA) was similar to that of vancomycin and tetracycline (MIC90, 1 g/mL) and
linezolid  (MIC90, 2 g/mL). The -haemolytic streptococci exhibited 100.0% susceptibility to
ceftaroline.  Ceftaroline activity against Escherichia coli, Klebsiella spp., and Enterobacter spp.
was  similar to that of ceftriaxone and ceftazidime. These parenteral cephalosporin agents
have  potent activity against non-extended-spectrum -lactamase-phenotype strains, but
are not active against extended-spectrum -lactamase-phenotype strains. These resultsconﬁrm  the in vitro activity of ceftaroline against pathogens common in community-
acquired  respiratory tract and skin and soft tissue infection in Latin America, and suggest
il co
3
13 Ethat  ceftaroline fosam
Introduction
© 20Ceftaroline, the active form of the prodrug ceftaroline
fosamil, is a new cephalosporin with in vitro activity
against both Gram-positive (including methicillin-resistant
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Este é um artigo Open Access sob a licençauld be an important therapeutic option for these infections.
Staphylococcus aureus [MRSA]) and common Gram-negative
bacteria.1,2 It has been approved by the USA-FDA for use
in  community-acquired bacterial pneumonia (CABP) and in
lsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND, North Liberty, IA 52317, USA.
acute bacterial skin and skin structure infections (ABSSSI).
It also has received marketing authorization in the Euro-
pean  Union for community-acquired pneumonia (CAP) and
 de CC BY-NC-ND
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omplicated skin and soft tissue infections (cSSTI).4 The
n  vitro activity of ceftaroline against pathogens associated
ith  CAP and cSSTI (as well as demonstrated clinical efﬁcacy)
ake  it an option for empiric monotherapy of these common
nfections.5–10
The emergence of drug-resistant bacteria causing CAP and
SSTI  has increased the potential for inappropriate initial ther-
py  in these infections.7–10 In CAP, multidrug resistance in
treptococcus pneumoniae has led to increased morbidity and
ortality.11–13 In cSSTI, the emergence of multidrug-resistant
RSA has led to increased ﬁnancial costs and increasing
umbers of patients with unsatisfactory treatment outcomes
ue  to decreasing therapy choices.7–9,14–16 The availability of
eftaroline, a -lactam with activity against MRSA and S.
neumoniae, provides a much  needed additional treatment
ption.1,2
With the commercial availability and use of ceftaroline
osamil, it is prudent to monitor activity of the drug against
acterial pathogens through surveillance studies to assess
ts  continued activity and gather information on emerging
esistance pathogens and mechanisms. The Assessing World-
ide  Antimicrobial Resistance Evaluation (AWARE) Program
s  such a monitoring program.17–20 In this report, we present
n  evaluation of ceftaroline and comparator antimicrobial
gents activity tested against 986 isolates from patients with
ommunity-acquired respiratory tract (CARTI) and skin and
oft  tissue (SSTI) infections as part of the AWARE Program in
atin  American (LATAM) medical centers during 2010.
aterials  and  methods
rganism  collection
 total of 986 isolates from the AWARE Program identiﬁed
s  CARTI or SSTI pathogens by the infection type and/or
pecimen site recorded by the submitting laboratory were
elected.  Isolates were from patients in 15 medical centers in
ve LATAM countries (country, number of medical centers):
rgentina (2), Brazil (6), Chile (2), Colombia (1) and Mexico
4).  There were  312 CARTI isolates (S. pneumoniae, 172 [55.1%];
aemophilus inﬂuenzae, 94 [30.1%]; and Moraxella catarrhalis,
6  [14.7%]) and 674 SSTI isolates (S. aureus, 370 [54.9%], -
aemolytic  streptococci, 67 [9.9%]; Escherichia coli, (120 [17.8];
lebsiella  spp. 75 [11.1%]; and Enterobacter spp., 42, [6.2%]).
usceptibility  testing
solates were  tested for susceptibility to ceftaroline and com-
arator  agents by reference broth microdilution methods.21
linical and Laboratory Standards Institute (CLSI) interpreta-
ions  were  based on criteria described in M100-S23.22 USA-FDA
reakpoints were  used for tigecycline in the absence of
LSI  interpretations.23 Isolates were  tested in cation-adjusted
ueller–Hinton broth (CA-MHB); supplemented with 2.5–5%
ysed  horse blood for streptococci.21 Haemophilus spp. were
21ested  in Haemophilus Test Medium. An extended spec-
rum  -lactamase (ESBL) phenotype was  determined as per
LSI  guidelines.22 Concurrent quality control (QC) testing was
erformed  to assure proper test conditions and procedures.3;1 7(5):564–572  565
QC strains included: S. aureus ATCC 29213, Enterococcus fae-
calis  ATCC 29212, S. pneumoniae ATCC 49619, H. inﬂuenzae ATCC
49247  and 49766, and E. coli ATCC 25922 and 35218. All QC
results  were within published CLSI ranges.22
Results
There were 172 S. pneumoniae isolates from CARTI, 48
(27.9%)  of which exhibited penicillin-intermediate suscep-
tibility  (Pen-I; MIC, 0.12–1 g/mL) and 38 (22.1%) penicillin
resistance (Pen-R, MIC, ≥2 g/mL). All strains were  inhibited
at  a ceftaroline MIC  of ≤0.5 g/mL with 100.0% of iso-
lates categorized22 as susceptible (Tables 1 and 2). The
MIC  range for ceftaroline against penicillin-susceptible S.
pneumoniae  (ceftaroline MIC, ≤0.008–0.03 g/mL) was  slightly
lower  than that of penicillin-intermediate (ceftaroline MIC,
≤0.008–0.12  g/mL) and penicillin-resistant (ceftaroline MIC,
0.12–0.5  g/mL) strains; see Tables 1 and 2. Ceftaroline was
four-  to eight-fold more  active against penicillin-intermediate
and eight-fold more  active against penicillin-resistant strains
than  ceftriaxone (Table 2). Ceftaroline was also 16-fold more
active  than amoxicillin-clavulanate against the penicillin-
intermediate strains and 32-fold more  active against the
penicillin-resistant isolates. All of the penicillin-intermediate
and -resistant isolates were  susceptible to ceftaroline, while
only  73.7% of the penicillin-resistant isolates were  susceptible
to  ceftriaxone (Table 2).
All 94 H. inﬂuenzae isolates were susceptible to ceftaro-
line with the highest MIC value at only 0.06 g/mL (Table 2).
The  MIC values for -lactamase producing strains (MIC50,
0.015  g/mL and MIC90, 0.03 g/mL) were slightly higher than
for  -lactamase-negative strains (MIC50 ≤ 0.008 and MIC90,
0.015  g/mL). Ceftaroline was  also highly active against the 46
isolates  of M.  catarrhalis tested, with a MIC90 at 0.12 g/mL and
a  MIC range at ≤0.008–0.5 g/mL (Table 1).
There  were a total of 370 S. aureus (50.3% MRSA) iso-
lates from SSTI infections (Tables 1 and 3). The ceftaroline
MIC50/90 for all S. aureus was  at 0.5/2 g/mL; 84.6% susceptible22
and no resistant strains (≥4 g/mL; see Table 3). Ceftaroline
activity against methicillin-susceptible S. aureus (MSSA) iso-
lates  (MIC50 and MIC90, 0.25 g/mL; 100% susceptible) was
four-  to eight-fold greater than noted for MRSA (MIC50/90,
1/2  g/mL; 69.4% susceptible) (Tables 1 and 3). The high-
est  MIC results observed among MSSA and MRSA were  0.5
and  2 g/ml, respectively (Table 3). Ceftaroline was  16-fold
more  active than ceftriaxone when tested against MSSA.
Most  agents tested against MSSA from SSTI exhibited a
high  rate of susceptibility (>90%; see Table 3); exceptions
were erythromycin and tetracycline (79.3 and 89.7%, respec-
tively).  Against all S. aureus (100.0% susceptible), linezolid
(MIC50/90, 1/2 g/mL), vancomycin (MIC50/90, 1/1 g/mL), dap-
tomycin (MIC50/90, 0.25/0.5 g/mL), and tigecycline (MIC50/90,
0.06/0.25 g/mL) were  the most active agents. Only 10.2% of
MRSA  strains were susceptible to levoﬂoxacin, 9.7% to eryth-
romycin,  and 13.4% to clindamycin (Table 3).All 67 strains of -haemolytic streptococci were susceptible
to  ceftaroline (MIC50/90, 0.015/0.015 g/mL; Table 3). Ceftaro-
line activity was  slightly greater against the Group A serogroup
(MIC50/90, ≤0.008/0.015 g/mL) than against Group B (MIC50/90,
566
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Table 1 – Cumulative % inhibited at each ceftaroline MIC  when testing contemporary pathogens from Latin American CARTI and SSTI infections (2010).
Organism group (no. tested) No. (cumulative % inhibited) at ceftaroline MIC in (g/ml):
≤0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 ≥4 MIC50 MIC90
Staphylococcus aureus (370) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.5) 17 (5.1) 158 (47.8) 39 (58.4) 97 (84.6) 57 (100.0) – 0.5 2
MSSA (184) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.1) 17 (10.3) 157 (95.7) 8 (100.0) – – – 0.25 0.25
MRSA (186) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 31 (17.2) 97 (69.4) 57 (100.0) – 1 2
Streptococcus pneumoniae (172) 81 (47.1) 24 (61.0) 16  (70.3) 11 (76.7) 34  (96.5) 5 (99.4) 1  (100.0) – – – 0.015 0.12
Penicillin-susceptible (86) 78 (90.7) 6 (97.7) 2  (100.0) – – – – – – – ≤0.008 ≤0.008
Penicillin-intermediate (48) 3 (6.3) 18  (43.8) 14  (72.9) 11 (95.8) 2 (100.0) – – – – – 0.03 0.06
Penicillin-resistant (38) 0 (0.0) 0  (0.0) 0  (0.0) 0  (0.0) 32  (84.2) 5 (97.4) 1 (100.0) – – – 0.12 0.25
-Haemolytic streptococci (67) 29 (43.3) 35 (95.5) 3 (100.0) – – – – – – – 0.015 0.015
Group A Streptococcus (24) 21 (87.5) 3 (100.0) – – – – – – – – ≤0.008 0.015
Group B Streptococcus (34) 0 (0.0) 31 (91.2) 3 (100.0) – – – – – – – 0.015 0.015
Other (9) 8 (88.9) 1 (100.0) – – – – – – – – ≤0.008 –
Escherichia coli (120) 0 (0.0) 0 (0.0) 5 (4.2) 18 (19.2) 31 (45.0) 10 (53.3) 2 (55.0) 0 (55.0) 3 (57.5) 51 (100.0) 0.25 >4
Non ESBL (67) 0 (0.0) 0 (0.0) 5 (7.5) 18 (34.3) 31 (80.6) 10 (95.5) 2 (98.5) 0 (98.5) 1 (100.0) – 0.12 0.25
ESBL phenotype (53) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (3.8) 51 (100.0) >4 >4
Klebsiella pneumoniae (67) 1 (1.5) 0 (1.5) 2 (4.5) 13 (23.9) 6 (32.8) 0 (32.8) 0 (32.8) 0 (32.8) 0 (32.8) 45 (100.0) >4 >4
Non ESBL (23) 1 (4.3) 0 (4.3) 2 (13.0) 13 (69.6) 6 (95.7) 0 (95.7) 0 (95.7) 0 (95.7) 0 (95.7) 1 (100.0) 0.06 0.12
ESBL phenotype (44) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 44 (100.0) >4 >4
Klebsiella oxytoca (8) 0 (0.0) 0  (0.0) 1  (12.5) 2 (37.5) 2 (62.5) 1 (75.0) 1 (87.5) 0 (87.5) 0 (87.5) 1 (100.0) 0.12 –
Non ESBL (7) 0 (0.0) 0 (0.0) 1 (14.3) 2 (42.9) 2 (71.4) 1 (85.7) 1 (100.0) – – – 0.12 –
ESBL phenotype (1) 0 (0.0) 0  (0.0) 0  (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) >4 –
Enterobacter spp. (42) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 12 (28.6) 7 (45.2) 2 (50.0) 1 (52.4) 0 (52.4) 20 (100.0) 0.5 >32
Haemophilus inﬂuenzae (94) 61 (64.9) 21 (87.2) 10 (97.9) 2 (100.0) – – – – – – ≤0.008 0.03
-Lactamase negative (72) 54 (75.0) 13 (93.1) 5 (100.0) – – – – – – – ≤0.008 0.015
-Lactamase positive (22) 7 (31.8) 8 (68.2) 5 (90.9) 2 (100.0) – – – – – – 0.015 0.03
Moraxella catarrhalis (46) 1 (2.2) 1 (4.3) 8 (21.7) 13 (50.0) 20 (93.5) 2 (97.8) 1 (100.0) – – – 0.06 0.12
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Table 2 – Activity of ceftaroline and comparator antimicrobial agents when tested against contemporary Latin American
CARTI pathogens (2010).
Organism (no. tested/antimicrobial agents) MIC (g/mL)
MIC50 MIC90 Range CLSIa %S/%R
Streptococcus pneumoniae (172)
Ceftaroline  0.015 0.12 ≤0.008 to 0.5 100.0/–
Ceftriaxone ≤0.06 1 ≤0.06 to 8 94.2/0.6
Penicillinb 0.06 2  ≤0.03 to 4 93.0/0.0
Penicillinc 0.06 2  ≤0.03 to 4 50.0/22.1
Amoxicillin/clavulanate ≤1 2 ≤1 to 8 91.3/4.7
Meropenem ≤0.12 0.5 ≤0.12 to 1 79.5/3.5
Erythromycin ≤0.06 >8 ≤0.06 to >8 71.5/27.3
Clindamycin ≤0.25 >1 ≤0.25 to >1 89.0/11.0
Levoﬂoxacin 1 1 ≤0.5 to 1 100.0/0.0
Trimethoprim/sulfamethoxazole ≤0.5 >4 ≤0.5 to >4 55.2/28.5
Tetracycline ≤0.25 >8 ≤0.25 to >8 76.2/21.5
Tigecyclined ≤0.03 ≤0.03 ≤0.03 to 0.06 100.0/–
Linezolid 1 1 0.25 to 2 100.0/–
Vancomycin 0.25 0.5 ≤0.12 to 0.5 100.0/–
S. pneumoniae PenI (48)
Ceftaroline  0.03 0.06 ≤0.008 to 0.12 100.0/–
Ceftriaxone 0.12 0.5 ≤0.06  to 1 100.0/0.0
Penicillinb 0.25 0.5 0.12 to 1 100.0/0.0
Penicillinc 0.25 0.5 0.12 to 1 0.0/0.0
Amoxicillin/clavulanate ≤1 ≤1 ≤1 to 2 100.0/0.0
Meropenem ≤0.12 ≤0.12 ≤0.12 to 0.5 97.9/0.0
Erythromycin ≤0.06 >8 ≤0.06 to >8 58.3/39.6
Clindamycin ≤0.25 >16 ≤0.25 to >16 81.3/18.8
Levoﬂoxacin 1 1 ≤0.5 to 1 100.0/0.0
Trimethoprim/sulfamethoxazole ≤0.5 4 ≤0.5 to >4 50.0/20.8
Tetracycline ≤0.25 >8 ≤0.25 to >8 72.9/27.1
Tigecyclined 0.03 0.03 ≤0.03 to 0.03 100.0/–
Linezolid 1 1 0.25 to 2 100.0/–
Vancomycin 0.25 0.5 ≤0.12 to 0.5 100.0/–
S. pneumoniae PenR (38)
Ceftaroline  0.12 0.25 0.12 to 0.5 100.0/–
Ceftriaxone 1 2 0.5 to 8 73.7/2.6
Penicillinb 2 4 2 to 4 68.4/0.0
Penicillinc 2 4 2 to 4 0.0/100.0
Amoxicillin/clavulanate 2 8 ≤1 to 8 60.5/21.1
Meropenem 0.5 1 0.25 to 1 10.5/15.8
Erythromycin 4 >8 ≤0.06 to >8 44.7/55.3
Clindamycin ≤0.25 >1 ≤0.25 to >1 76.3/23.7
Levoﬂoxacin 1 1 ≤0.5 to 1 100.0/0.0
Trimethoprim/sulfamethoxazole >4 >4 1 to >4 0.0/89.5
Tetracycline 0.5 >8 ≤0.25 to >8 57.9/42.1
Tigecyclined ≤0.03 ≤0.03 ≤0.03 to 0.06 100.0/–
Linezolid 1 1 0.5 to 2 100.0/–
Vancomycin 0.25 0.5 0.25 to 0.5 100.0/–
H. inﬂuenzae (94)
Ceftaroline  ≤0.008 0.03 ≤0.008 to 0.06 100.0/–
Ampicillin ≤1 >8 ≤1 to >8 76.6/23.4
Amoxicillin/clavulanate ≤1 ≤1 ≤1 to 4 100.0/0.0
Ceftriaxone ≤0.06 ≤0.06 ≤0.06 100.0/–
Cefuroxime 0.5 2 ≤0.12 to 4 100.0/0.0
Tetracycline 0.5 0.5 ≤0.25 to >8 97.9/2.1
Trimethoprim/sulfamethoxazole ≤0.5 >4 ≤0.5 to >4 69.1/27.7
Azithromycin 1 2 ≤0.06 to 4 100.0/–
Levoﬂoxacin ≤0.5 ≤0.5 ≤0.5 100.0/–
M. catarrhalis (46)
Ceftaroline  0.06 0.12 ≤0.008 to 0.5 –/–
Penicillin >4 >4 0.25 to >4 –/–
Amoxicillin/clavulanate ≤1 ≤1 ≤1 100.0/0.0
Ceftriaxone 0.25 0.5 ≤0.06 to 1 100.0/–
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Table 2 – (Continued)
Organism (no. tested/antimicrobial agents) MIC (g/mL)
MIC50 MIC90 Range CLSIa %S/%R
Cefuroxime 1 2 0.25 to 4 100.0/0.0
Tetracycline ≤0.25 ≤0.25 ≤0.25 to 0.5 100.0/0.0
Trimethoprim/sulfamethoxazole ≤0.5 1 ≤0.5 to >4 89.1/2.2
Levoﬂoxacin ≤0.5 ≤0.5 ≤0.5 100.0/–
a Criteria as published by the CLSI.22
b Criteria as published by the CLSI [2013] for ‘Penicillin parenteral (non-meningitis)’.
n V)’.c Criteria as published by the CLSI [2013] for ‘Penicillin oral (penicilli
d USA-FDA breakpoints were applied.23
0.015/0.015 g/mL). All Group A isolates and 91.2% of Group
B  isolates exhibited a MIC  value of ≤0.015 g/mL and there
were  only 3 Group B isolates at the highest MIC value of
0.03  g/mL (Table 1). Tetracycline susceptibility for the Group
A  serotype strains was  62.5% (data not shown). Susceptibil-
ity  was  95.8% for erythromycin, clindamycin, and levoﬂoxacin
(data  not shown). For the Group B serotype, tetracycline sus-
ceptibility  was  17.5%, while for erythromycin and clindamycin
it  was  at 94.1% (data not shown).
A total of 44.2% of E. coli isolates were  an ESBL-phenotype
(Table 1). The ceftaroline MIC  range for all E. coli was  0.03 to
>32  g/mL with 55.0% of the isolates exhibiting susceptibility22
to ceftaroline (MIC50/90, 0.25/>32 g/mL) (Table 3). Ceftaroline
was  very potent against the non-ESBL-phenotype E. coli with a
MIC50/90 at 0.12/0.25 g/mL; 98.5% susceptible at ≤0.5 g/mL.22
Decreased susceptibility was  exhibited by other agents such as
ampicillin-sulbactam (41.8%), gentamicin (89.6%), tetracycline
(43.3%),  and levoﬂoxacin (71.6%) for the non-ESBL-phenotype
strains (Table 3). Susceptibility rates were decreased even fur-
ther for these agents against the ESBL-phenotype strains with
susceptibility  rates ranging from 5.7% (ampicillin-sulbactam)
to 54.7% (gentamicin) (data not shown). None of the ESBL-
phenotype strains tested were susceptible to ceftaroline.
For  K. pneumoniae, ceftaroline was  highly active against
the  non-ESBL-phenotype strains (MIC50/90, 0.06/0.12 g/mL;
95.7%  susceptible) while susceptibility for levoﬂoxacin (87.0%)
and  tetracycline (87.0%) was  decreased (Table 3). All ESBL-
phenotype strains were resistant to ceftaroline with concur-
rently  low susceptibility to gentamicin (34.1%), levoﬂoxacin
(36.4%), and tetracycline (68.2%; data not shown). The high-
est  ceftaroline MIC  value for the seven non-ESBL phenotype
Klebsiella oxytoca strains was  0.5 g/mL while the one ESBL-
phenotype strain was  ceftaroline resistant (Table 1).
Enterobacter spp. exhibited a ceftaroline MIC50 and MIC90 at
0.5  and >32 g/mL, respectively for 42 isolates (Tables 1 and 3).
The  ceftaroline susceptibility rate was  similar at 50.0% to that
of  ceftriaxone (52.4%).
Discussion
Ceftaroline demonstrated in vitro activity against the most
common  CARTI and SSTI pathogens isolated from patients in
15 LATAM medical centers. It was  the most active agent tested
against  the CARTI pathogen S. pneumoniae with a MIC90 value
that  was  eight-fold lower than ceftriaxone, levoﬂoxacin, andlinezolid.  Ceftaroline’s spectrum of coverage (at 100.0% sus-
ceptible)  was  similar to tigecycline, linezolid, and vancomycin.
All  of the above agents retained activity against penicillin-
resistant strains (penicillin MIC, ≥2 g/mL). Ceftaroline was
the  most active agent tested against H. inﬂuenzae (100.0%
susceptible, MIC90, 0.03 g/mL) and M.  catarrhalis (MIC90,
0.12  g/mL; no interpretive criteria available). When tested
against  S. aureus, the activity of ceftaroline was similar to that
of  vancomycin and tetracycline (MIC90, 1 g/mL) and linezolid
(MIC90, 2 g/mL). However, its coverage was  reduced relative to
these  agents, as 15.4% of the staphylococci exhibited MIC val-
ues  at 2 g/mL, which is the CLSI intermediate susceptibility
category for ceftaroline.22 Against the -haemolytic strepto-
cocci,  the activity of ceftaroline was similar to daptomycin,
linezolid, vancomycin, tigecycline, meropenem, penicillin and
ceftriaxone;  all providing complete (100.0%) coverage. The cef-
taroline activity against E. coli, and Klebsiella spp. was  similar to
that of ceftriaxone and ceftazidime. These agents have potent
activity  against non-ESBL phenotype strains, but should be
considered  inactive against ESBL-phenotype Enterobacteri-
aceae.
Pfaller and colleagues20 conducted an evaluation of the
activity  of ceftaroline over a three year period in the USA
(2008–2010). The ceftaroline MIC90 reported by Pfaller et al.
for  S. pneumoniae was  0.12 g/mL with 98.7% of MIC  values
≤0.25  g/mL. Ceftaroline was shown to be 16-fold more  active
than  ceftriaxone.20 Further the MIC90 values for H. inﬂuenzae
and  M.  catarrhalis, respectively, were 0.015 and 0.12 g/mL. A
total  of 99.9% of H. inﬂuenzae were susceptible to ceftaroline;
there are no interpretive criteria available for M. catarrhalis.
In  this 2010 LATAM AWARE Program report, the MIC90 for
S.  pneumoniae was  also at 0.12 g/mL and susceptibility was
at  100.0% using CLSI breakpoint criteria.22 The MIC90 for H.
inﬂuenzae  was  lower in this study at 0.03 g/mL when com-
pared  to the Pfaller et al.20 study, with identical MIC90 values
for  M. catarrhalis (0.12 g/mL).
The activity of ceftaroline against SSTI pathogens from the
2010  LATAM surveillance presented here is comparable to that
reported  by Jones et al. from an international 2008 surveillance
program conducted in the USA and Europe regions.5 In that
study,  the S. aureus MIC50/90 for ceftaroline was  0.5/1 g/mL,
as  compared to 0.5/2 g/mL in this 2010 LATAM sample. Jones
et  al. reported that there were regional differences for MRSA,
with  the MIC50/90 for ceftaroline in Europe at 1/2 g/mL while
it  was at 1/1 g/mL for the USA.5 The LATAM population of
MRSA  in this study, as with the European collection reported
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Table 3 – Activity of ceftaroline and comparator antimicrobial agents when tested against contemporary Latin American
SSTI pathogens (2010).
Organism (no. tested/antimicrobial agents) MIC (g/mL)
MIC50 MIC90 Range CLSIa %S/%R
Staphylococcus aureus (370)
Ceftaroline  0.5 2 0.06 to 2 84.6/0.0
Ceftriaxone 8 >8 1 to >8 49.7/50.3
Oxacillin >2 >2 ≤0.25 to >2 49.7/50.3
Meropenem 1 >8 ≤0.12 to >8 49.7/50.3
Erythromycin >4 >4 ≤0.25 to >4 44.3/54.1
Clindamycin ≤0.25 >2 ≤0.25 to >2 54.6/45.1
Levoﬂoxacin ≤0.5 >4 ≤0.5 to >4 52.7/45.9
Trimethoprim/sulfamethoxazole ≤0.5 ≤0.5 ≤0.5 to >4 97.0/3.0
Tetracycline ≤0.25 1 ≤0.25 to >8 92.7/6.2
Tigecyclineb 0.06 0.25 ≤0.03 to 0.5 100.0/–
Linezolid 1 2 0.5 to 2 100.0/0.0
Vancomycin 1 1 0.5 to 2 100.0/0.0
Daptomycin 0.25 0.5 0.12 to 1 100.0/–
MRSA (186)
Ceftaroline 1 2 0.25 to 2 69.4/0.0
Ceftriaxone >8 >8 8 to >8 0.0/100.0
Oxacillin >2 >2 >2 0.0/100.0
Meropenem >8 >8 0.5 to >8 0.0/100.0
Erythromycin >4 >4 ≤0.25 to >4 9.7/89.8
Clindamycin >2 >2 ≤0.25 to >2 13.4/86.6
Levoﬂoxacin >4 >4 ≤0.5 to >4 10.2/88.7
Trimethoprim/sulfamethoxazole ≤0.5 ≤0.5 ≤0.5 to >4 94.6/5.4
Tetracycline ≤0.25 1 ≤0.25 to >8 95.7/4.3
Tigecyclineb 0.06 0.25 ≤0.03 to 0.5 100.0/–
Linezolid 1 1 0.5 to 2 100.0/0.0
Vancomycin 1 1 0.5 to 2 100.0/0.0
Daptomycin 0.25 0.5 0.25 to 1 100.0/–
MSSA (184)
Ceftaroline 0.25 0.25 0.06 to 0.5 100.0/0.0
Ceftriaxone 4 4 1 to 8 100.0/0.0
Oxacillin 0.5 0.5 ≤0.25 to 1 100.0/0.0
Meropenem ≤0.12 ≤0.12 ≤0.12 to 0.25 100.0/0.0
Erythromycin ≤0.25 >4 ≤0.25 to >4 79.3/17.9
Clindamycin ≤0.25 ≤0.25 ≤0.25 to >2 96.2/3.3
Levoﬂoxacin ≤0.5 ≤0.5 ≤0.5 to >4 95.7/2.7
Trimethoprim/sulfamethoxazole ≤0.5 ≤0.5 ≤0.5 to >4 99.5/0.5
Tetracycline ≤0.25 8 ≤0.25 to >8 89.7/8.2
Tigecyclineb 0.06 0.25 ≤0.03 to 0.5 100.0/–
Linezolid 1 2 0.5 to 2 100.0/0.0
Vancomycin 1 1 0.5 to 2 100.0/0.0
Daptomycin 0.25 0.5 0.12 to 0.5 100.0/–
-haemolytic streptococci (67)
Ceftaroline  0.015 0.015 ≤0.008 to 0.03 100.0/–
Penicillin ≤0.03 0.06 ≤0.03 to 0.06 100.0/–
Ceftriaxone ≤0.06 0.12 ≤0.06 to 0.12 100.0/–
Meropenem ≤0.12 ≤0.12 ≤0.12 100.0/–
Erythromycin ≤0.25 ≤0.25 ≤0.25 to >4 94.0/6.0
Clindamycin ≤0.25 ≤0.25 ≤0.25 to >2 94.0/6.0
Levoﬂoxacin ≤0.5 1 ≤0.5 to 4 98.5/0.0
Trimethoprim/sulfamethoxazole ≤0.5 ≤0.5 ≤0.5 to >4 –/–
Tetracycline >8 >8 ≤0.25 to >8 37.3/62.7
Tigecyclineb ≤0.03 ≤0.03 ≤0.03 to 0.06 100.0/–
Linezolid 1 1 0.5 to 1 100.0/–
Vancomycin 0.5 0.5 0.25 to 0.5 100.0/–
Daptomycin 0.12 0.25 ≤0.06 to 0.25 100.0/–
E. coli (120)
Ceftaroline 0.25 >32 0.03 to >32 55.0/45.0
Ceftazidime 0.25 32 0.06 to >32 67.5/26.7
Ampicillin >8 >8 2 to >8 17.5/82.5
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Table 3 – (Continued)
Organism (no. tested/antimicrobial agents) MIC (g/mL)
MIC50 MIC90 Range CLSIa %S/%R
Ampicillin/sulbactam 16 >32 1 to >32 25.8/40.0
Piperacillin/tazobactam 2 16 1 to >64 90.8/3.3
Tetracycline >8 >8 0.5 to >8 32.5/67.5
Tigecyclineb 0.12 0.5 0.06 to 1 100.0/0.0
Ceftriaxone ≤0.06 >8 ≤0.06 to >8 57.5/42.5
Gentamicin ≤1 >8 ≤1 to >8 74.2/25.8
Levoﬂoxacin 4 >4 ≤0.5 to >4 49.2/49.2
Meropenem ≤0.12 ≤0.12 ≤0.12 100.0/0.0
E. coli non-ESBL (67)
Ceftaroline  0.12 0.25 0.03 to 2 98.5/1.5
Ceftazidime 0.12 0.25 0.06 to 0.5 100.0/0.0
Ampicillin >8 >8 2 to >8 31.3/68.7
Ampicillin/sulbactam 16 32 1 to >32 41.8/19.4
Piperacillin/tazobactam 2 4 1 to 64 98.5/0.0
Tetracycline >8 >8 0.5 to >8 43.3/56.7
Tigecyclineb 0.12 0.5 0.06 to 1 100.0/0.0
Ceftriaxone ≤0.06 ≤0.06 ≤0.06 to 0.12 100.0/0.0
Gentamicin ≤1 >8 ≤1 to >8 89.6/10.4
Levoﬂoxacin ≤0.5 >4 ≤0.5 to >4 71.6/26.9
Meropenem ≤0.12 ≤0.12 ≤0.12 100.0/0.0
K. pneumoniae (67)
Ceftaroline  >32 >32 ≤0.008 to >32 32.8/67.2
Ceftazidime 16 >32 0.03 to >32 46.3/52.2
Ampicillin >8 >8 ≤1 to >8 6.0/94.0
Ampicillin/sulbactam >32 >32 ≤0.25 to >32 32.8/64.2
Piperacillin/tazobactam 16 >64 ≤0.5 to >64 53.7/35.8
Tetracycline 2 >8 0.5 to >8 74.6/20.9
Tigecyclineb 0.5 1 0.12 to 4 97.0/0.0
Ceftriaxone >8 >8 ≤0.06 to >8 34.3/65.7
Gentamicin ≤1 >8 ≤1 to >8 56.7/41.8
Levoﬂoxacin 1 >4 ≤0.5 to >4 53.7/46.3
Meropenem ≤0.12 8 ≤0.12 to >8 82.1/14.9
K. pneumoniae non-ESBL (51)
Ceftaroline  0.06 0.12 ≤0.008 to 4 95.7/4.3
Ceftazidime 0.12 0.25 0.03 to 1 100.0/0.0
Ampicillin >8 >8 ≤1 to >8 17.4/82.6
Ampicillin/sulbactam 4 8 ≤0.25 to >32 95.7/4.3
Piperacillin/tazobactam 2 4 ≤0.5 to >64 95.7/4.3
Tetracycline 1 8 0.5 to >8 87.0/4.3
Tigecyclineb 0.25 0.5 0.12 to 2 100.0/0.0
Ceftriaxone ≤0.06 0.12 ≤0.06 to 0.5 100.0/0.0
Gentamicin ≤1 ≤1 ≤1 100.0/0.0
Levoﬂoxacin ≤0.5 >4 ≤0.5 to >4 87.0/13.0
Meropenem ≤0.12 ≤0.12 ≤0.12 100.0/0.0
K. oxytoca (8)
Ceftaroline 0.12 – 0.03 to 16 87.5/12.5
Ceftazidime 0.06 – 0.06 to 0.5 100.0/0.0
Ampicillin >8 – >8 0.0/100.0
Ampicillin/sulbactam 4 – 2 to >32 75.0/25.0
Piperacillin/tazobactam 1 – 1 to >64 87.5/12.5
Tetracycline 1 – 0.5 to 1 100.0/0.0
Tigecyclineb 0.12 – 0.12 to 0.5 100.0/0.0
Ceftriaxone ≤0.06 – ≤0.06 to 2 87.5/0.0
Gentamicin ≤1 – ≤1 100.0/0.0
Levoﬂoxacin ≤0.5 – ≤0.5 to 1 100.0/0.0
Meropenem ≤0.12 – ≤0.12 100.0/0.0
Enterobacter spp. (42)
Ceftaroline  0.5 >32 0.12 to >32 50.0/47.6
Ceftazidime 1 >32 0.12 to >32 64.3/33.3
Ampicillin >8 >8 2 to >8 7.1/92.9
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Table 3 – (Continued)
Organism (no. tested/antimicrobial agents) MIC (g/mL)
MIC50 MIC90 Range CLSIa %S/%R
Ampicillin/sulbactam 32 >32 4 to >32 21.4/57.1
Piperacillin/tazobactam 4 >64 1 to >64 66.7/14.3
Tetracycline 2 >8 1 to >8 76.2/16.7
Tigecyclineb 0.25 1 0.12 to 4 95.2/0.0
Ceftriaxone 1 >8 ≤0.06 to >8 52.4/45.2
Gentamicin ≤1 >8 ≤1 to >8 71.4/23.8
Levoﬂoxacin ≤0.5 >4 ≤0.5 to >4 73.8/23.8
Meropenem ≤0.12 ≤0.12 ≤0.12 to 0.5 100.0/0.0
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ra Criteria as published by the CLSI, -lactam susceptibility should be
b USA-FDA breakpoints were applied.23
y Jones et al.,5 contains more  strains of MRSA at the MIC
alue  of 2 g/mL. This may  be due to MRSA clonal differences
etween regions. A reduction in S. aureus with an MIC value
t  2 g/mL in the USA has been shown by Farrell et al. to
oincide with a shift toward the USA300 clone.18 Ceftaroline
as  also noted to be active against Enterobacteriaceae that
re  of the non-ESBL phenotype while it has limited activity
gainst  ESBL-producing organisms or strains overexpressing
mpC.1,5,17 This activity was  consistent with other third gen-
ration  cephalosporins such as ceftazidime and ceftriaxone.
In  summary, ceftaroline demonstrated in vitro activity
gainst a collection of contemporary Gram-positive and -
egative  pathogens from LATAM, associated with CARTI and
STI  infections. This suggests that ceftaroline fosamil merits
urther  study in LATAM for these clinical indications.
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